TMS Related Biomarker Assessments
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xiaoming Du, PhD
- Phone Number: 410-402-6036
- Email: xdu@som.umaryland.edu
Study Contact Backup
- Name: Kimberly Tate
- Phone Number: 410-402-6008
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21228
- University of Maryland, Baltimore
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and Female between ages 18-65
- Ability to give written informed consent (age 18 or above)
- Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above10.
Exclusion Criteria:
- Any history of seizures.
- Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.
- Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, CNS infection or tumor, other significant brain neurological conditions.
- Taking > 400 mg clozapine/day
- Failed TMS screening questionnaire
- Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.
- History of head injury with loss of consciousness over 10 minutes; history of brain surgery
- Can not refrain from using alcohol and/or marijuana 24 hours or more & cigarette smoking half and hour or more prior to experiments.
- Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self report; or by positive pregnancy test) or has had unprotected sexual intercourse without birth control in the last 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Active rTMS first and sham rTMS second
Participants in this arm will receive active rTMS in one visit first, then receive sham rTMS in another visit.
|
Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.
|
|
Other: Sham rTMS first and active rTMS second
Participants in this arm will receive sham rTMS in one visit first, then receive active rTMS in another visit.
|
Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of Resting-state Functional Connectivity (rsFC) by Active and Sham rTMS
Time Frame: 2 weeks
|
The strength of rsFC was first defined by correlation coefficient (r).
Because the distribution of r values is highly skewed, z scores (normally distributed) were computed via fisher r-to-z transform.
The z score central value (i.e., z score of 0) represents no relationship between the two brain regions.
A positive (negative) z score indicates a positive (negative) association between the two brain regions.
Stronger rsFC (i.e., larger positive z score) was related to stronger connection between the two brain regions.
The differences of rsFC between active and sham were reported.
A positive (negative) value of rsFC change suggests the rsFC was enhanced (weakened) by active TMS.
|
2 weeks
|
|
Change of Mismatch Negativity (MMN) From Electroencephalography (EEG) Signals by Active and Sham rTMS
Time Frame: 2 weeks
|
TMS effect is explored by comparing MMN changes from active and sham rTMS.
MMN is measured by subtracting the averaged EEG response to a set of standard stimuli from the averaged response to rarer deviant stimuli, and taking the amplitude of this difference wave in a given time window.
The differences of MMN between active and sham were reported.
A negative (positive) value of rsFC change suggests the MMN was enhanced (weakened) by active TMS.
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Xiaoming Du, PhD, University of Maryland, Baltimore
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HP-00103592
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.